Skip to main content

Apheresis Unit (Hematology)

Apherisis is a procedure that makes it possible to separate the various elements of the blood, in particular: 

  • the plasma (therapeutic plasmapherisis),
  • the red corpuscles (therapeutic erythropheresis),
  • the white corpuscles (therapeutic leucapheresis),
  • the hematopoietic stem cells (cytapheresis), essential for both analogous transplants (using cells taken from the patient) and allogenic transplants (using the cells of another donor). 

Apheresis is a technique of extraction by centrifugation in an extracorporeal blood circuit (CEC). The components not collected are reinjected into the donor. 

The Apheresis Unit at the Jules Bordet Institute receives, for the ULB-IRIS network as a whole, patients likely to benefit from the collection of stem cells. The Unit works in close cooperation with the various autotransplant centres for adults and with the Children's Hospital (HUDERF). 

We have been practicing apheresis in our service since 1970, with a nursing and technical staff trained especially for the purpose. Three doctors and four nurses are available and ensure the continuity of the medical care, in cooperation with the hematology service as a whole. The Unit has an emergency service that operates 24 hours a day. 

The extraction, handling and conservation of the hematopoietic stem cells is in accordance with good practices. Since 2009 we have been accredited under the inspection programme (JACIE, the "Joint Accreditation Committee of the ISCT and EBMT" ) which makes it possible to improve quality within the various teams involved in carrying out the hematopoietic transplants.  

The Apheresis Unit at the Jules Bordet Institute also gives our patients access to treatment using photopheresis. This treatment is indicated for Chronic Graft Versus Host Disease (CGVHD) that does not respond to the standard treatment and in certain cases of skin lymphomas. 

 

Research projects


 

Project 1

A Phase II study to assess the safety and the efficacy of extracorporeal photopheresis using the Theraflex ECP™ for patients with refractory chronic GVHD
  • Project Initiator : Philippe Lewalle
  • Collaboration(s) : Protocole de la société belge d’hématologie
  • Financing (or) support: Amis de l’Institut Bordet

Our team

Responsible Physician
Prof Philippe Lewalle - Hematologist

Doctor
Dr Adriano Salaroli

Head Nurse
Patrick Crombez

Nurse(s)
Corine Mal
Walter Bellemans
Denise Duthoit
Nicoletta Munteanu
Olivier Mugema

Qualitician
Aurélie Timmermans
Olivier Carabin

Secretariat
Vanessa Vanpevenage

13/01/2020

 Scientific publications

Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer.

Authors : Sonnenblick A, Salmon-Divon M, Salgado R, Dvash E, Pondé N, Zahavi T, Salmon A, Loibl S, Denkert C, Joensuu H, Ameye L, Van den Eynden G, Kellokumpu-Lehtinen PL, Azaria A, Loi S, Michiels S, Richard F, Sotiriou C
Year : 2020
Journal : Int J Cancer
Volume : 147
Pages : 266-276

Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.

Authors : Thieblemont C, Howlett S, Casasnovas RO, Mounier N, Perrot A, Morschhauser F, Fruchart C, Daguindau N, Van Eygen K, Obéric L, Bouabdallah R, Pica GM, Nicolas-Virezelier E, Abraham J, Fitoussi O, Snauwaert S, Eisenmann JC, Lionne-Huyghe P, Bron D, Tricot S, Deeren D, Gonzalez H, Costello R, Le Du K, da Silva MG, Grosicki S, Trotman J, Catalano J, Caballero D, Greil R, Cohen AM, Gaulard P, Roulin L, Takeshita K, Casadebaig ML, Tilly H, Coiffier B
Year : 2020
Journal : Br J Haematol
Volume : 189
Pages : 84-96

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.

Authors : Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, Kim K, Zamagni E, Rodriguez-Otero P, Renwick W, Rose C, Tempescul A, Boyle E, Manier S, Attal M, Moreau P, Macro M, Leleu X, Lorraine Chretien M, Ludwig H, Guo S, Sturniolo M, Tinel A, Silvia Monzini M, Costa B, Houck V, Hulin C, Yves Mary J
Year : 2020
Journal : Leukemia
Volume : 34
Pages : 224-233

Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma.

Authors : Manson G, Brice P, Herbaux C, Silva MG, Bouabdallah K, Deau B, Bouteloup J, Schiano JM, Nicolas-Virelizier E, Maerevoet M, Ghesquieres H, Stamatoullas A, Antier C, Carlo-Stella C, de Charette M, Poizeau F, Dercle L, Houot R
Year : 2020
Journal : Eur J Nucl Med Mol Imaging

Identification of Acute Myeloid Leukemia Bone Marrow Circulating MicroRNAs.

Authors : Moussa Agha D, Rouas R, Najar M, Bouhtit F, Naamane N, Fayyad-Kazan H, Bron D, Meuleman N, Lewalle P, Merimi M
Year : 2020
Journal : Int J Mol Sci
Volume : 21